查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1947932

個人化基因治療市場分析及預測（至2035年）：依類型、產品、服務、技術、應用、最終使用者、流程、部署及階段分類

Personalized Gene Therapies Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Process, Deployment, Stage
出版日期: | 出版商: Global Insight Services | 英文 354 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

個人化基因治療市場預計將從2024年的12億美元成長到2034年的58億美元，複合年成長率約為20.7%。個人化基因治療市場是指根據個體基因譜量身定做的治療方法，旨在糾正遺傳疾病的根本原因。該市場整合了先進的基因組學、生物資訊學和生物技術，以開發客製化治療方法，從而提高療效並最大限度地減少副作用。遺傳疾病盛行率的上升以及CRISPR和基因編輯技術的進步是推動市場成長的主要因素。關鍵趨勢包括監管核准的增加以及生物技術公司之間為加速創新和提高可及性而開展的合作。

個人化基因治療市場正經歷強勁成長，這主要得益於基因組學的進步和對客製化治療日益成長的需求。腫瘤領域成長最為迅猛，這主要源自於對標靶癌症治療以改善患者預後的需求。 CAR-T細胞療法和基因編輯技術處於腫瘤領域的前沿，展現出巨大的創新和療效潛力。罕見疾病領域也緊隨其後，個人化治療為那些治療選擇有限的疾病帶來了希望。基因替代療法和RNA治療方法作為解決疾病潛在遺傳病因的手段，正日益受到關注。心血管領域，特別是針對心臟疾病的基因治療，也成為一個充滿前景的領域，目前相關研究和臨床試驗正在進行中。對先進遞送系統和監管支援的投資進一步推動了市場成長。生技公司和研究機構之間日益密切的合作有望加速治療方法的研發，為相關人員帶來盈利的回報。

市場區隔
類型 體細胞基因治療、生殖細胞基因治療、體內基因治療、體外基因治療
產品 病毒載體、非病毒載體、基因編輯工具、質體DNA、RNA療法
服務 基因篩檢、診斷、客製化基因合成​​、臨床試驗和監管支持
科技 CRISPR、TALENs、鋅指核酸酶、反義寡核苷酸、 RNA干擾
目的 腫瘤科、罕見疾病科、心血管疾病科、神經系統疾病科、眼科、代謝性疾病科
最終用戶 醫院、生技公司、製藥公司、研究機構、學術機構
流程 基因轉殖、基因編輯、基因靜默、基因替換
部署 臨床、商業、研究
步 藥物發現、臨床前試驗、臨床試驗、商業化

在個人化基因治療市場，市場佔有率日益受到主要企業定價策略和創新產品推出的影響。各公司致力於透過價格競爭來搶佔市場佔有率，同時持續投資於新型治療方法的研發。這導致新產品上市數量激增，拓展了治療選擇，並推動了市場發展。該市場的特點是策略競爭，各公司競相推出治療方法以滿足未滿足的醫療需求，從而實現盈利成長。競爭基準分析顯示，市場競爭異常激烈，成熟企業和新興生技公司都在爭奪主導地位。監管影響，尤其是在北美和歐洲，在塑造市場動態發揮關鍵作用。這些地區制定了嚴格的標準，影響企業的市場准入和擴大策略。競爭格局的特點是策略聯盟、併購，旨在加強產品平臺並擴大地理覆蓋範圍。監管發展、技術進步和策略夥伴關係將共同塑造市場的未來，並帶來巨大的成長潛力。

主要趨勢和促進因素：

個人化基因治療市場正經歷顯著成長，這主要得益於基因組技術的進步和精準醫療領域投資的不斷增加。人工智慧（AI）和機器學習在基因治療研究中的應用是關鍵趨勢，它提高了治療方案開發的準確性和效率。此外，生物技術公司與學術機構之間的合作正在加速創新並推動市場發展。監管部門對基因治療核准的支持也是關鍵促進因素，簡化的核准流程有助於加速產品進入市場。遺傳性疾病和罕見疾病的日益普遍凸顯了個人化治療的必要性，進一步推動了市場需求。此外，以患者為中心的治療理念也日益受到關注，強調個別化治療能夠改善治療效果並提高患者滿意度。新興市場擁有日益完善的醫療基礎設施和不斷提高的基因治療意識，因此蘊藏著巨大的機會。能夠成功應對監管環境並提供具成本效益解決方案的公司有望佔據顯著的市場佔有率。在技​​術突破和對個人化醫療的關注推動下，個人化基因治療市場預計將持續成長。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 體細胞基因治療
    • 種系基因治療
    • 體內基因治療
    • 體外基因治療
  • 市場規模及預測：依產品分類
    • 病毒載體
    • 非病毒載體
    • 基因編輯工具
    • 質體DNA
    • RNA療法
  • 市場規模及預測：依服務分類
    • 基因篩檢
    • 諮詢
    • 客製化基因合成
    • 臨床試驗
    • 監管支持
  • 市場規模及預測：依技術分類
    • CRISPR
    • TALENs
    • 鋅指核酸酶
    • 反義寡核苷酸
    • RNA干擾
  • 市場規模及預測：依應用領域分類
    • 腫瘤學
    • 罕見疾病
    • 心血管疾病
    • 神經系統疾病
    • 眼科
    • 代謝性疾病
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 生技公司
    • 製藥公司
    • 研究所
    • 學術機構
  • 市場規模及預測：依製程分類
    • 基因轉移
    • 基因編輯
    • 基因靜默
    • 基因替換
  • 市場規模及預測：依發展狀況
    • 臨床
    • 商業
    • 研究
  • 市場規模及預測：依階段分類
    • 藥物發現
    • 臨床前
    • 臨床試驗
    • 商業化

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章：公司簡介

  • Bluebird Bio
  • Sangamo Therapeutics
  • uni Qure
  • REGENXBIO
  • Krystal Biotech
  • Orchard Therapeutics
  • Logic Bio Therapeutics
  • Passage Bio
  • Intellia Therapeutics
  • Editas Medicine
  • Beam Therapeutics
  • Precision Bio Sciences
  • CRISPR Therapeutics
  • Rubius Therapeutics
  • Homology Medicines
  • Repligen
  • Voyager Therapeutics
  • Cellectis
  • Meira GTx
  • Freeline Therapeutics

第9章：關於我們

簡介目錄
Product Code: GIS32578

Personalized Gene Therapies Market is anticipated to expand from $1.2 billion in 2024 to $5.8 billion by 2034, growing at a CAGR of approximately 20.7%. The Personalized Gene Therapies Market encompasses treatments tailored to individual genetic profiles, aiming to correct genetic disorders at their source. This market integrates advanced genomics, bioinformatics, and biotechnology to develop bespoke therapies, enhancing efficacy and minimizing side effects. Rising prevalence of genetic disorders and advancements in CRISPR and gene editing technologies are propelling growth. Key trends include increasing regulatory approvals and collaborations among biotech firms to accelerate innovation and accessibility.

The Personalized Gene Therapies Market is experiencing robust growth, propelled by advancements in genomics and increasing demand for tailored treatments. The oncology segment leads in performance, driven by the need for targeted cancer therapies that improve patient outcomes. Within oncology, CAR-T cell therapies and gene editing techniques are at the forefront, offering significant potential for innovation and effectiveness. The rare diseases sub-segment follows closely, as personalized approaches offer hope for conditions with limited treatment options. Gene replacement and RNA-based therapies are gaining prominence, addressing the underlying genetic causes of these diseases. The cardiovascular segment, focusing on gene therapies for heart conditions, is also emerging as a promising area, with ongoing research and clinical trials. Investments in advanced delivery systems and regulatory support are further accelerating market growth. The increasing collaboration between biotech firms and research institutions is poised to enhance therapeutic development, offering lucrative opportunities for stakeholders.

Market Segmentation
TypeSomatic Gene Therapy, Germline Gene Therapy, In Vivo Gene Therapy, Ex Vivo Gene Therapy
ProductViral Vectors, Non-Viral Vectors, Gene Editing Tools, Plasmid DNA, RNA Therapeutics
ServicesGenetic Screening, Consulting, Custom Gene Synthesis, Clinical Trials, Regulatory Support
TechnologyCRISPR, TALENs, Zinc Finger Nucleases, Antisense Oligonucleotides, RNA Interference
ApplicationOncology, Rare Diseases, Cardiovascular, Neurological Disorders, Ophthalmology, Metabolic Disorders
End UserHospitals, Biotechnology Companies, Pharmaceutical Companies, Research Institutes, Academic Institutions
ProcessGene Delivery, Gene Editing, Gene Silencing, Gene Replacement
DeploymentClinical, Commercial, Research
StageDiscovery, Preclinical, Clinical Trials, Commercialization

In the Personalized Gene Therapies Market, market share is increasingly influenced by the pricing strategies of key players and the introduction of innovative products. Companies are focusing on competitive pricing to capture market share, while simultaneously investing in the research and development of novel therapies. This dynamic has led to a surge in new product launches, enhancing treatment options and driving market evolution. The landscape is marked by a strategic race to introduce therapies that address unmet medical needs, thus opening lucrative avenues for growth. Competition benchmarking reveals a highly competitive environment with established players and emerging biotech firms vying for dominance. Regulatory influences, particularly in North America and Europe, play a pivotal role in shaping market dynamics. These regions set stringent standards that impact market entry and expansion strategies. The competitive landscape is characterized by strategic collaborations, mergers, and acquisitions aimed at enhancing product pipelines and expanding geographical reach. The market's future is shaped by regulatory developments, technological advancements, and strategic partnerships, promising significant growth potential.

Geographical Overview:

The personalized gene therapies market is witnessing notable growth across various regions, each exhibiting unique dynamics. North America leads the market, driven by advanced healthcare infrastructure and substantial investments in genetic research. The presence of key biotech firms and supportive regulatory frameworks further accelerates the market's expansion. Europe follows closely, with strong governmental support for personalized medicine and a robust research ecosystem. The region's emphasis on precision healthcare and patient-centric approaches enhances its market position. In Asia Pacific, the market is burgeoning, propelled by rising healthcare expenditures and increasing awareness of personalized therapies. Countries like China and India are emerging as significant players due to their large patient pools and growing biotech sectors. Latin America and the Middle East & Africa present promising growth pockets. In Latin America, increasing investments in healthcare innovation are evident, while the Middle East & Africa are recognizing the potential of personalized gene therapies to address regional health challenges effectively.

Global tariffs and geopolitical tensions are significantly impacting the Personalized Gene Therapies Market. In Japan and South Korea, reliance on imported raw materials for gene therapy vectors is prompting strategic investments in local biomanufacturing capabilities to mitigate tariff-induced costs. China is accelerating its domestic biotech sector, driven by export restrictions and a push for self-sufficiency in gene-editing technologies. Taiwan, with its advanced biotech infrastructure, remains pivotal but is vulnerable to cross-strait tensions. The global market for personalized gene therapies is expanding, driven by technological advancements and increasing demand for tailored treatments. By 2035, the market is expected to evolve with stronger regional collaborations and innovation hubs. Middle East conflicts may indirectly affect supply chains through fluctuating energy prices, impacting operational costs and logistics.

Key Trends and Drivers:

The personalized gene therapies market is experiencing a remarkable surge, propelled by advancements in genomic technologies and increasing investment in precision medicine. A key trend is the integration of artificial intelligence and machine learning in gene therapy research, enhancing the accuracy and efficiency of treatment development. Additionally, collaborations between biotech firms and academic institutions are accelerating innovation, driving the market forward. Regulatory support for gene therapy approvals is another significant driver, as streamlined pathways encourage faster market entry. The rising prevalence of genetic disorders and rare diseases underscores the need for personalized therapies, further boosting demand. Moreover, patient-centric approaches are gaining traction, emphasizing tailored treatments that improve outcomes and patient satisfaction. Opportunities abound in emerging markets, where healthcare infrastructure is improving and awareness of genetic therapies is growing. Companies that can navigate regulatory landscapes and offer cost-effective solutions are poised to capture significant market share. The personalized gene therapies market is set for sustained growth, driven by technological breakthroughs and a focus on individualized care.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Process
  • 2.8 Key Market Highlights by Deployment
  • 2.9 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Somatic Gene Therapy
    • 4.1.2 Germline Gene Therapy
    • 4.1.3 In Vivo Gene Therapy
    • 4.1.4 Ex Vivo Gene Therapy
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Viral Vectors
    • 4.2.2 Non-Viral Vectors
    • 4.2.3 Gene Editing Tools
    • 4.2.4 Plasmid DNA
    • 4.2.5 RNA Therapeutics
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Genetic Screening
    • 4.3.2 Consulting
    • 4.3.3 Custom Gene Synthesis
    • 4.3.4 Clinical Trials
    • 4.3.5 Regulatory Support
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 CRISPR
    • 4.4.2 TALENs
    • 4.4.3 Zinc Finger Nucleases
    • 4.4.4 Antisense Oligonucleotides
    • 4.4.5 RNA Interference
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Oncology
    • 4.5.2 Rare Diseases
    • 4.5.3 Cardiovascular
    • 4.5.4 Neurological Disorders
    • 4.5.5 Ophthalmology
    • 4.5.6 Metabolic Disorders
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals
    • 4.6.2 Biotechnology Companies
    • 4.6.3 Pharmaceutical Companies
    • 4.6.4 Research Institutes
    • 4.6.5 Academic Institutions
  • 4.7 Market Size & Forecast by Process (2020-2035)
    • 4.7.1 Gene Delivery
    • 4.7.2 Gene Editing
    • 4.7.3 Gene Silencing
    • 4.7.4 Gene Replacement
  • 4.8 Market Size & Forecast by Deployment (2020-2035)
    • 4.8.1 Clinical
    • 4.8.2 Commercial
    • 4.8.3 Research
  • 4.9 Market Size & Forecast by Stage (2020-2035)
    • 4.9.1 Discovery
    • 4.9.2 Preclinical
    • 4.9.3 Clinical Trials
    • 4.9.4 Commercialization

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Process
      • 5.2.1.8 Deployment
      • 5.2.1.9 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Process
      • 5.2.2.8 Deployment
      • 5.2.2.9 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Process
      • 5.2.3.8 Deployment
      • 5.2.3.9 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Process
      • 5.3.1.8 Deployment
      • 5.3.1.9 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Process
      • 5.3.2.8 Deployment
      • 5.3.2.9 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Process
      • 5.3.3.8 Deployment
      • 5.3.3.9 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Process
      • 5.4.1.8 Deployment
      • 5.4.1.9 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Process
      • 5.4.2.8 Deployment
      • 5.4.2.9 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Process
      • 5.4.3.8 Deployment
      • 5.4.3.9 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Process
      • 5.4.4.8 Deployment
      • 5.4.4.9 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Process
      • 5.4.5.8 Deployment
      • 5.4.5.9 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Process
      • 5.4.6.8 Deployment
      • 5.4.6.9 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Process
      • 5.4.7.8 Deployment
      • 5.4.7.9 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Process
      • 5.5.1.8 Deployment
      • 5.5.1.9 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Process
      • 5.5.2.8 Deployment
      • 5.5.2.9 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Process
      • 5.5.3.8 Deployment
      • 5.5.3.9 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Process
      • 5.5.4.8 Deployment
      • 5.5.4.9 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Process
      • 5.5.5.8 Deployment
      • 5.5.5.9 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Process
      • 5.5.6.8 Deployment
      • 5.5.6.9 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Process
      • 5.6.1.8 Deployment
      • 5.6.1.9 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Process
      • 5.6.2.8 Deployment
      • 5.6.2.9 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Process
      • 5.6.3.8 Deployment
      • 5.6.3.9 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Process
      • 5.6.4.8 Deployment
      • 5.6.4.9 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Process
      • 5.6.5.8 Deployment
      • 5.6.5.9 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Bluebird Bio
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Sangamo Therapeutics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 uni Qure
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 REGENXBIO
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Krystal Biotech
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Orchard Therapeutics
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Logic Bio Therapeutics
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Passage Bio
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Intellia Therapeutics
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Editas Medicine
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Beam Therapeutics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Precision Bio Sciences
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 CRISPR Therapeutics
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Rubius Therapeutics
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Homology Medicines
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Repligen
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Voyager Therapeutics
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Cellectis
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Meira GTx
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Freeline Therapeutics
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us